RCT with 24 patients treated with potassium canrenoate and 25 placebo patients in Poland, showing no significant differences.
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 4 of 24 (16.7%), control 5 of 25 (20.0%), NNT 30.
|
risk of ICU admission, 10.7% lower, RR 0.89, p = 1.00, treatment 6 of 24 (25.0%), control 7 of 25 (28.0%), NNT 33.
|
relative TFS score, 30.4% better, RR 0.70, p = 0.51, treatment 24, control 25.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Kotfis et al., 2/5/2022, Randomized Controlled Trial, placebo-controlled, Poland, Europe, peer-reviewed, 10 authors, study period December 2020 - August 2021, trial
NCT04912011.
Contact:
katarzyna.kotfis@pum.edu.pl (corresponding author), igor.karolak@gmail.com, kacper.lechowicz@gmail.com, mazegan@wp.pl, apikulska@wp.pl, paulina.niedzwiedzka-rystwej@usz.edu.pl, kawamilosz@gmail.com, jsien@poczta.onet.pl, aleksandra.szylinska@gmail.com, mwisniewska35@gmail.com.